150. Urinary Tract-Associated Gram-Negative Bacteremia: Impact of Treatment Duration

Jasmin K. Badwal, PharmD; Elizabeth O. Hand, PharmD, BCPS, BCIDP; John M. Lyons, PharmD, BCPS and Kristi A. Traugott, PharmD, BCPS, BCIDP; University Health System, San Antonio, Texas

Session: 37. Bacteremia, CLABSI, and Endovascular Infections *Thursday, October 3, 2019: 12:15 PM*

Background. Gram-negative bloodstream infections are one of the leading causes of death in the United States. A select number of studies have been conducted evaluating various treatment durations; however, none have specifically focused on urinary sources. The purpose of this study was to compare the effect of short vs. long course of antimicrobial therapy on clinical and microbiological outcomes for urinary tract-associated gram-negative bacteremia (GNB).

Methods. This was a single-center, retrospective review from January 2016 to October 2018. Subjects were screened using a report of all positive GNB cultures. Hospitalized patients \geq 18 years of age were included if they had a bacteremia from a urinary source and received an intravenous or a highly bioavailable oral agent for \geq 7 days. Patients were excluded due to pregnancy, incarceration, inappropriate definitive therapy, polymicrobial bacteremia, unaddressed source control issues, or death during the treatment course. Short course (SC) was defined as 7–10 days, while long course (LC) was defined as >10 days. The primary composite outcome of treatment failure included both 30-day all-cause mortality and 90-day recurrence. Secondary outcomes included 30-day re-admission, 90-day mortality, resistance development, and C. difficile infection.

Results. A total of 207 patients were included: 45 patients received SC and 162 received LC. Both groups were similar at baseline in terms of comorbidities, intensive care unit (ICU) admission, and vasopressor initiation. No statistically significant difference in the primary composite endpoint was observed: 2/45 (4.4%) SC vs. LC 10/162 (6.2%), P = 0.66. There was also no difference in other secondary outcomes.

Conclusion. Consistent with prior studies, we were unable to find a significant difference in clinical failure rates between SC vs. LC for treatment of urinary tract-associated GNB. Generalizability to more complicated cases including those with inadequate source control may be limited; however, these data add to the body of literature supporting the use of shorter antibiotic durations.

Disclosures. All authors: No reported disclosures.

151. Comparing the Clinical Utility of Rapid Diagnostic Tests for Gram-Negative Bloodstream Infection Using a Desirability of Outcomes Ranking

Kimberly C. Claeys, PharmD⁵; Kathryn Schlaffer, MD²; Zegbeh Kpadeh-Rogers, PhD³; Yunyun Jiang, PhD⁴; Scott R. Evans, PhD⁴; J. Kristie Johnson, PhD, D(ABMM)⁵ and Surbhi Leekha, MBBS, MPH⁶; ¹School of Pharmacy, University of Maryland, Baltimore, Maryland; ²Mercy Medical Center, Baltimore, Maryland; ³University of Maryland Medical Center, Baltimore, Maryland; ⁴The George Washington University, Rockville, Maryland; ⁵Department of Pathology, University of Maryland, Baltimore, Maryland; ⁶Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland

Session: 37. Bacteremia, CLABSI, and Endovascular Infections *Thursday, October 3, 2019: 12:15 PM*

Background. Rapid diagnostic testing (RDT) technology in bloodstream infections (BSI) has outpaced provider understanding of how to effectively use it. To optimize the use of RDT platforms and antibiotic therapy, decision makers must determine which RDTs to implement at their institutions. A thorough understanding of which platform to choose extends beyond simple analytic measures of sensitivities and specificities and should include a robust analysis of how these RDTs could impact clinical decisions.

Methods. Retrospective study of adult patients with Gram-negative (GN) BSI from at University of Maryland Medical Center. The clinical microbiology laboratory used Verigene® BC-GN in clinical practice. Discarded blood samples were run on BioFire® FilmArray BCID. Final organism identification/susceptibility, antibiotic exposures, and clinical outcomes were reviewed. DOOR was applied to theoretical therapy decisions based on both actual prescribing adherence to institutional algorithm recommendations; 1 being most and 6 being least desirable (Table 1). A partial credit scoring system was applied to DOOR from most (100) to least desirable (0) outcome. Comparisons were made in a paired manner.

Results. 77 patients met inclusion. The median age was 58 (IQR 47, 68), 44.2% were in the ICU, and 75.3% had ID consult within 24 hours of BSI. Organism identification included: $E.\ coli\ (35.1\%),\ K.\ pneumoniae\ (23.4\%),\ P.\ mirabilis\ (10.4\%),\ S.\ marcescens\ (10.4\%),\ Enterobacter\ spp.\ (9.4\%),\ P.\ aeruginosa\ (3.9\%). The only resistance determinant was CTX-M (11.6%). An antibiotic change occurred in 26.2% of cases, divided between antibiotic escalation and de-escalation. Based on the actual utilization of RDT results, median DOOR was not different between BC-GN and BCID (3 [IQR 3.4] vs. 4 [IQR 3.4], <math>P=0.44$). Using a partial credit scoring system, the mean score was not different between platforms (49.8 [SD 26.8] vs. 47.7 [SD 20.3], P=0.44). Through pairwise comparisons, BC-GN would have resulted in an optimal outcome of 15.3% (95% CI 4.7% to 19.3%) more often than BCID.

Conclusion. Based on the actual use of RDTs for GN BSI there was no difference in potential clinical outcomes between platforms in this relatively small sample. DOOR is a novel mechanism to quantitate clinical utility and compare RDTs.

| Rank | Outcome |
|------|--|
| 1 | Escalation to effective therapy |
| 2 | De-escalation to effective therapy |
| 3 | No change, empiric therapy optimal |
| 4 | No change, empiric therapy effective |
| 5 | Inappropriate escalation to effective therapy |
| 6 | Inappropriate de-escalation or change to ineffective therapy |

Disclosures. All authors: No reported disclosures.

152. Brevibacterium species: Case Series and Literature Review of an Emerging Opportunistic Cause of Bloodstream Infections

FNU Shweta, MBBS; Pooja Gurram, MBBS; Sarwat Khalil, MBBS; Kyle Rodino, PhD and John C. O'Horo, Sr., MD, MPH; Mayo Clinic, Rochester, Minnesota

Session: 37. Bacteremia, CLABSI, and Endovascular Infections Thursday, October 3, 2019: 12:15 PM

Background. Brevibacterium species are non-motile, catalase-positive, obligate aerobic gram-positive bacilli. Colonies are yellow to gray-white, non-hemolytic, smooth, 6.5% sodium chloride tolerant. *B. fermentans* post neurosurgical meningitis was first described in 1969 in an infant. *B. casei* remains the most commonly isolated species (Table 4). The most commonly reported syndromes are bloodstream infections (BSIs) and endocarditis. Despite these reports, this organism continues to be listed on CDC's NHSN commensal database.

Methods. Isolates of *Brevibacterium* from clinical samples at Mayo Clinic, Rochester from January 1, 2014 to December 31, 2018 were identified. Charts were reviewed to determine patient demographics, immune status, source of culture, comorbidities, antibiotic susceptibility test (AST), length of stay (LOS) in hospital ani intensive care unit (ICU), and mortality. Likelihood ratio (L-R) and Pearson correlation coefficient (PCC) of nominal data were calculated using the Chi-square test and Fischer exact test (FET). We defined statistical significance as $P \leq 0.05$.

Results. We identified 48 isolates from 45 unique patients, 46% were females. Distribution of age, hospital and ICU LOS, and time to culture growth, and AST data are shown in Table 1. 15.5% patients received allogeneic or autologous stem cell (SCT), or solid-organ transplant (SOT) recipients. 89% cultures were from sterile sources and 68.75% were blood cultures. Of these, 63.64% were monomicrobial. 62% of isolates identified to species level were *B. casei.* 5 patients were treated; an additional 10 received active antibiotics for other indications. Statistically significant variables are reported in Tables 2 and 3. Thirty-day mortality was 13%. This was higher in patients with bacteremia (L-R: 5.3 [P=0.02]) but FET was not statistically significance (P=0.15).

Conclusion. Accurate diagnosis of *Brevibacterium* may require molecular techniques. At our center, SCT or SOT recipient status and recent chemotherapy were associated with bacteremia. In these patients, this organism could represent an opportunistic cause of BSI. AST data suggest that Vancomycin offers a reasonable empiric treatment option. Additional data are needed to further define host populations in whom this organism presents pathogenicity.

Table 1: Secondary Variables and Antimicrobial Susceptibility Test Results

| Parameter | Unit | Median | Interquartile Range |
|-------------------------------|-------------------------|--------------------|---------------------|
| Age | Years | 59 | 51 – 72 |
| Hospital Length of Stay (LOS) | Days | 6 | 4-17 |
| Intensive Care Unit LOS | Days | 1 | 0-2.5 |
| Time to Growth | Hours | 57 | 46.25 – 85.5 |
| Antibiotic | Susceptible (%) | Intermediate (%) | Resistant (%) |
| Allabout | Susceptible (70) | interinediate (70) | itesistant (70) |
| Vancomycin | 7/7 (100) | 0 | 0 |
| 1.0.00.00.00.00 | | | , , |
| Vancomycin | 7/7 (100) | 0 | 0 |
| Vancomycin Penicillin | 7/7 (100) 2/7 (28.5) | 0 4/7 (57) | 0 1/7 (14) |

Table 2: Likelihood of Bacteremia by Transplant Status

| Likelinood of Bacteremia by Transplar | | | | | |
|---------------------------------------|--|-------------------------------|-------------|--|--|
| Count Total % Col % Row % | Other Source of Positive Culture | Blood Culture | Total | | |
| No Transplant | 15 33.33 100.00 39.47 | 23 51.11 76.67 60.53 | 38 84.44 | | |
| Transplant | 0 0.00 0.00 0.00 | 7 15.56 23.33 100.00 | 7 15.56 | | |
| Total | 15 33.33 | 30 66.67 | 45 | | |
| Test | | Chi | P - | | |

| Test | Chi | Р- | |
|------------------|--------|--------|--|
| | Square | value | |
| Likelihood Ratio | 6.304 | 0.0120 | |
| Pearson | 4.145 | 0.0418 | |

Table 3: Likelihood of Bacteremia by Recent Chemotherapy

| Count Total % Col % Row % | Other Source of Positive Culture | Blood Culture | Total |
|------------------------------------|--|------------------|-------|
| | 15 | 21 | 36 |
| No Recent | 33.33 | 46.67 | 80.00 |
| Chemotherapy | 100.00 | 70.00 | |
| (1.55) | 41.67 | 58.33 | |
| | 0 | 9 | 9 |
| Recent | 0.00 | 20.00 | 20.00 |
| Chemotherapy | 0.00 | 30.00 | |
| | 0.00 | 100.00 | |
| Total | 15 | 30 | 45 |
| Total | 33.33 | 66.67 | |

| Test | Chi Square | P - value | |
|------------------|---------------|--------------|--|
| Likelihood Ratio | 8.384 | 0.0038* | |
| Pearson | 5.625 | 0.0177* | |

| | Fourty of Grigory Face Reported | | Spains/ Enginees has | renovageness have | Different Garage Strike | | Microsing |
|--|--|---|---|--|--|---|--------------|
| N' | 84/200 | Fort a Salt Wildred | # com/ southful | No Street Security and Eyean april | S Flar, Reg. Eur, Ser, Lts, Mar. | What had not all a had a had a had a | |
| | Fenal IES | Selection | E condens/19 (Statements) | | S Yes, No., No., Ann. Ann. Ann. Services. Orleans. | FO Columns & Class | |
| OV. | Euch 2004 | fearer Interests | 5 mm/3/5/2/201 | (in these days haby world) | Author IV No. Inc. | Th Pillips CE on table 27 days 9 72 Berfassion NE on date | |
| , | Table Ann | | I any account | Shreti Cardinasa, Ontehap (II) | Griden TC Van Laur 60 Sto, Northwart 60 Sto, Northwart 60 Sto TC Van 61 Sto, Northwart | TO ATTER & SAN. | ľ |
| | Turney years | GRAPE TORREST | 8.00(NA)/11 | 996 MA | Private San, Gare, San, Sty. Co. | Name of Adrian Co. | |
| , | 6407.854 | Telepoig FR father account fatherin | 4 may 200 0011 | - | Tables | Name of the advisor | |
| | | | | 840 | | FORM, Scharin | |
| N. W. | Index(VIII | breegiatidate | E widdle life 65% gave reporting | - | 6 Year, Co., Day 1 Part | W Enterenting S. (ig 100) Paraboration (E.g. (cit) Abstractions (100 og 100) W No. W W Eg gjille & Sale | |
| 24 | 10K/301 | Feet traumation also feet traumation and traumation | E com/ A1 Coryec/stellification out tom | - | Filter, Cells, Eve, Ere, Cip, Yan | Mildelin English Ensu - Specifichaetr sys Figs. | |
| 74 | Brigary 2012 | Felipsing FS Calture account Ferborita | d may be distance expenses | - | 6 May Cay, Gay, F.C., Sany, 1 Fays, Gay | Finds Vigoziala Viala | |
| | 2003 | | | | A Colombia | tuned of this feature | |
| D/M | Sens/ 200 | 10 Cathelor accordand Perfords | Berdalmin u/Unique | Gre Orhan | S Chia, Elia, Gan, TC, ToPY YMR | #Orbital Califor Entail (Mail | * |
| V W | Street Will | Set a tarricipal returned | Embersely in different features | - | B Glip, Pay, Fair. | Name of other Wilderstein and Addis and Agents | |
| NI NI | | fight for wound address to the same | APVianyra biumbaniamyosen | | | | 100 |
| 0/ M (II) | Helm/ 2011 | Pan Roas | E may 14 millipare acquiring | No. One of the Department of SPE regime for present of the SPE regime for the SPE regime for present of the SPE regime for pr | 5 6w, 0p, 04b, 0m, Van | M Editorina Spirito 3 nd + PE Anti o Keda | |
| ~~ | Fena/ Illin | Sente Sedestry | 8 modern/16 mMpressparing | - | S SE Van Ame, dauge dies B Telephole, Sep. Sec. | Distant | |
| No. | Twitness (1876) | DE séction | E comp' delegan | to the second se | | NY COLL 10 COLD IN THE RESIDENCE WITH THE STREET AND THE STREET | |
| W. | 5,000,000 | Feriantis | £ mm/ Primare | District | Decreed securities to 2 letters 5 Get, Co. So. MC FC No. | Wife + 33 day (with remod | 7 |
| W.W. | A RECORD | Engaration labor | E may An Grown Hamiltonian nation | 100 | B Ang, American description, City From Printer Stee Stee St. M. City Code and conferences. | Wite all time | |
| M. | Turned 1981 | Social | Engel(M) Citizen | (04-50) (14 | Same Same | (As being) | Total |
| Maroun M | | | | | | | Unterprise |
| N . | ME, 16A/3001 | Frantisco Value Endocarditis | E widely 1 to 45A perceptioning | - | S Yan, San, Co, Mf, Lin, authorising Code | NY Vie 2 g 80 x 8 ms = M Switzenschilding 80 x fine 2 mls + FS Astrinomych x 16 marshs | * |
| Y' | (righted) 2000 | Farmente (CAPS) | g month partition of | - | Pirtus, beg, Sale, Soy, Say, San, Van | Profesion Generalists Gala | |
| N/F2IR | (whates/309 | Factorial III | E com/ A1 Corpor transferring son | AGE | Territoria (accompliation reconstrations) | M Sp + 14 Spp. Free College | |
| N * | Sweet 1987 | Fertures (DFS) | E Autrony Art Caryon transferation system | - | Fr Ds. Officials, exitain is Out, Van, 199/018, Ora, Any, Educates, Editor Inc. | F Op 16 og/molege | * |
| ing a | (whates) (65 | fearer teaunie | # mw/ A1 (ayus tiantiturian ayram | Settolar challes bronze | Intrast | Th Pow 4g/10 + her 200 mg data s 54 max Th Pow 4g/10 + his service of mg/10+ 36 data | * |
| | School 186 | teg fen fritte | projected with favore oursification surface | 84. | tringer | F3 Contract - 35 Sec. | |
| W. | Fenal 3894 | Familiani basistania | Emerited VII Seven duraffusion autom | Sendadari Sendana 1 diasmi MC | 6 tes Con 75 des 60 fan 7 co | D. O'Lo. Hall and M. Andreic November 19 days | |
| MI CONTRACT | (waster/itt) | handenamen | Laws service/benesis manus | | S. Frit, Martin, Str. Str., Facharper, S. Rich Street, Str. Str., No. 5 to 4 Shaper | TE INTELER IN MET AT THE | - |
| | | | | - | | | |
| N/M | 04,344 | DT Medius | E specially transes | Differ Standy-Stan | 5 Fes. Sty. Res. 15, days, Oxford His | the season by | |
| ribra) (ribrarium | Fena/IRIX | Famporation montages. | E Jernenbry Drinson | - | P. Fer, St. T.L. Chib P. Mattodio, Tothyllox | Distant | Untergree |
| eusprian/anterior - Firms epotits, Piper - Piperschin, lymber, dende dataffon in Leitzeits in begin maken prohibilit | uhige Mas (papienare, Yar - Yarige) Extra: cutacion, NPT - Mange, ben ejarana igloria ester distantas solutes | on, die - Bertomon, Ban-Bertanion, Inti-Imp erk, fureirumisk, filtrabote | over, (in - sineald, Nor - Marqueour, Are - Arcolotto, | herne (hangein, ill) - Staat I haan lefunar, (ISE - Constituena H - Nemojolin, lus - (welfenoli), fig - Epitholoin, (inh - Editor | | morad Sirgini, Milli a Impared monumentationing Systems, Millioh St. F. Marin, account of Suffernitron accos, Mill - Millionips, Cod Cod. Section, Cob Electrong Marins, Visi a Nov. | place, Amp - |
| Security Streets | III, et a., devide mon noplema harm han, t., et at., Maryon months of the Au- | n Frederick com our president and a re- | and Retained Stemates Montain Co. 217 NO. | 1 a 10P4M a 10P 1900 a 204 | | | |
| | | remove of relaying pertinents. IND Care from 2014. Percentage of teaching point infection 2 little Marketon. | | | | | |
| Sans, A. | , a a, his maney anhybriding Aa. | m Parker was now Arrange of Austral Wa | a j. 2010 439 p. 70 ž M species deniglasijes Purk Parlies, 1955, 1956 p. 745 h. Hobert Oguntario - Bandon Millando and Parlies applications | | | | |
| 04.13 | , et al., foramene goods of performe | species were going personal distribution on the | nous agreem Swelschrum on Asstan agreements sumpatent priese. An 1964-Dis. 2013. 2015 p. 1074. | ROWNERS MED TO A 18-1. | | | |
| | | (deinabers in arimmunony war prober) (i p. no., mit et/, for a hunor otto discuspe in i | | | | | |
| | | p no, liste at from a haromania distributa. A disebadanya ip in printerpolongolari vone artho a funcioni. Chi Microballetto, 2011, 150. | | 93 x 3694. | | | |
| | | | | | | | |
| | | en genincia parteri si ili denni i prophe pri sulli | min Hamaning's (fluiday), 2000, XG(0) p. 181-1 | | | | |
| igure, i | | | | | | | |
| Span, I Span, I Span, I | C. et al., Perfections in Development | | | | | | |
| Sent, V Span, S Sea, A Vanish Season | C. et al., Performance in Development (*), et al., Development count approxima- (*), et al., Development count approxima- | Diparted James 44 (CC) (Co Mirela), 200 | 980 y 7534. | | | | |
| Service Span, I Stan, II Vanes Span Spans Spans Spans Spans Spans Spans Spans | C. et al., Reductional de Devisionique P. et al., Devisionistrice contragation of L. et al., Devisionistrice contragation L. et al., Devisionistrice devisionistrice L. et al., Responsible contraction des in the | Dispersión (misso estra di C.) Con Missolini, 2000. Contra del missolini del menero de Carlo (missolini. Contra del missolini del m | MI(I) p. 703-4. Templarini, tema siripi p. 6764. Burullin Mandad Inton III, 1965 (4(16) p. 1864). | | | | |
| Sense V Openia Cons. A? Vancous Senses Senses Senses Senses Senses | C. d. A., Perfections to Devianterius P., et al., Devianterius cost application L. d. d., Devianterius cost application L. d. d., State than Advantagement A. d. d., An articulation of a mile March | Dispersor James et al (1) (1) Mineral (10) Communication of the state of the communication of | 900 p. 2024. The plants, print 1/9) p. 1/44. No Jille Marchinel (Marchinel L. 1965 14(16) p. 1864. Professor Ser (Title Ministral advants, 1960 14(16) p. 876.4 (Control Ser (184 1853 p. 4046. Control Ser (184 1853 p. 4046. | | | | |

Disclosures. All authors: No reported disclosures.

153. A Review of Ten Cases of Pulmonic Valve Infective Endocarditis

Harry E. Hicklin, MD; Glen Huang, DO; Kyle A. Davis, PharmD; Erin W. Barnes, MD and James E. Peacock, Jr., MD; Wake Forest Baptist Medical Center, Winston-Salem, North Carolina

Session: 37. Bacteremia, CLABSI, and Endovascular Infections *Thursday, October 3, 2019: 12:15 PM*

 $\label{eq:background.} Background. \quad \text{Pulmonic valve (PV) infective endocarditis (IE) is a rare entity, accounting for $\sim 1.5-2\%$ of all cases of IE. As a result, published literature describing the diagnosis and management of patients with PVIE is limited.}$

Methods. A retrospective review of patients ≥18 years old admitted to Wake Forest Baptist Medical Center from 2012 to 2017 with a diagnosis of PVIE based on the modified Duke criteria was performed.

Results. Ten patients were identified as having PVIE, 9 of whom had isolated PV involvement and 1 of whom had concurrent aortic valve involvement. The diagnosis of IE was definite per the modified Duke criteria in 8 patients. The median age was 41 years and 30% were female. Two patients had pacemakers, 1 had a prosthetic PV, and 1 had congenital heart disease. Six patients were identified as persons who inject drugs (PWID). On admission, 5 patients manifested fever and 5 had a documented murmur. Seven patients had septic pulmonary emboli with 4 of 7 patients manifesting pulmonary hypertension. Transthoracic echocardiography (TTE) revealed vegetations in 4 of 10 patients whereas PV vegetations were demonstrated in all 8 patients undergoing transesophageal echocardiography (TEE). S. aureus was the most common causative organism, accounting for 5 of the cases of PVIE with four of the five isolates being methicillin-resistant. Bacteremia persisted for a median of 3 days. One patient underwent PV replacement. The planned median duration of antimicrobial therapy was 6 weeks. The median length of stay was 18 days. Three patients died during the index hospitalization, 1 of whom was a PWID. No episodes of repeat PVIE occurred within 1 year.

 $\label{eq:conclusion.} PVIE \ is a rare disease. Only 40% of our patients had vegetations on TTE in contrast to a reported diagnostic yield of >90% in the literature. As such, PVIE may be underdiagnosed. S aureus was the most common organism isolated, which is$

in keeping with prior reports. PWID appear to be at high risk for PVIE. In view of the worsening opioid epidemic, more research on PVIE is warranted.

Disclosures. All authors: No reported disclosures.

154. Do I Really Need a Transesophageal Echo? Comparing Echocardiographic Modalities in Native Valve Infective Endocarditis due to Methicillin-Resistant Staphylococcus aureus

James Livesay, DO¹; William Lorson, DO¹; R. Eric Heidel, PhD¹ and Mahmoud Shorman, MD²; ¹Graduate School of Medicine, University of Tennessee, Knoxville, Tennessee; ²University of Tennessee, Knoxville, Tennessee

Session: 37. Bacteremia, CLABSI, and Endovascular Infections Thursday, October 3, 2019: 12:15 PM

Background. Methicillin-resistant Staphylococcus aureus (MRSA) infective endocarditis (IE) is associated with high morbidity and mortality. Management commonly includes six-weeks of antibiotics and surgical intervention, if the patient has complications. Current guidelines recommend obtaining an echocardiogram. Transesophageal echocardiogram (TEE) is preferred over transthoracic echocardiogram (TTE). We wanted to evaluate the role of a TEE in changing management of MRSA IE.

Methods. A retrospective cohort of patients with MRSA IE was analyzed between January 2013 and July 2017 at a tertiary care facility in East Tennessee. Patients with prosthetic valves or cardiac devices were excluded. Demographic, echocardiographic, antibiotic, blood culture, mortality, and intravenous drug use data were collected (Figure 1).


Results. Seventy-eight patients met the inclusion criteria. TTE was performed on 73 patients while five patients proceeded directly to TEE. Of the 73 patients that had a TTE, 33 (45.2%) detected the presence of vegetation and 40 (54.8%) did not. Of the 33 patients with a positive TTE, 15 subsequently underwent TEE, confirming IE. Out of the 40 patients with a negative TTE, 34 underwent TEE, of which 22 (64.7%) showed a vegetation. (Figure 2). A total of ten patients (12.8%) from the study underwent surgery. Of these ten, three (30%) had a positive TTE only, with no subsequent TEE. Five (50%) had both a positive TTE and TEE, and two (20%) had a negative TTE but positive TEE.

Conclusion. Transthoracic echocardiogram was adequate to visualize vegetations in 45.2% of patients. Completing a TEE increased the sensitivity of visualizing a vegetation, but management was most often not altered. Only two patients (5%) with a negative TTE, but positive TEE proceeded to surgery because of the findings. This causes us to question whether a subsequent TEE needs to be pursued when a TTE is negative in the setting of definite or possible IE by the modified Duke criteria. Even if a vegetation is seen on TEE the patient would most likely receive the same treatment, 6 weeks of intravenous antibiotics, as if no vegetation was seen. Forgoing a TEE reduces risk to the patient of undergoing a procedure, and reduces costs to the health-care system.

Figure 1. Demographic Data

| Age | Mean= 38 years | Range= 20-74 years | |
|--------------------------|---------------------------|--|---------------------------------|
| Race | White= 72 (92.3%) | Black= 3 (3.9%) | Unable to Determine= 3 (3.9%) |
| Intravenous Drug Use | Yes= 63 (80.8%) | No= 15 (19.2%) | |
| Hepatitis C Infection | Yes= 39 (50%) | No= 39 (50%) | |
| Disposition | Discharged= 58 (74.4%) | Left Against Medical Advice= 10 (12.8%) | Expired in Hospital= 10 (12.8%) |
| Gender | Male= 40 (51.3%) | Female= 38 (48.7%) | |

Figure 2. Imaging modality and results.



Disclosures. All authors: No reported disclosures.

155. A Case Series of Patients with Gemella Endocarditis

Abarna Ramanathan, BMBCh¹; Steven M. Gordon, MD² and Nabin K. Shrestha, MD, MPH¹; ¹Cleveland Clinic, Cleveland Heights, Ohio; ²Cleveland Clinic Foundation, Cleveland, Ohio

 $\begin{array}{l} \textbf{Session: 37. Bacteremia, CLABSI, and Endovascular Infections} \\ \textit{Thursday, October 3, 2019: } 12:15\ PM \end{array}$